Arsenic trioxide - Medsenic

Drug Profile

Arsenic trioxide - Medsenic

Alternative Names: Trisenox

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Medsenic
  • Developer Medsenic; Nantes University Hospital
  • Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Graft-versus-host disease; Systemic lupus erythematosus

Most Recent Events

  • 21 Dec 2016 Chemical structure information added
  • 01 Dec 2016 Phase-II clinical trials in Graft-versus-host disease in France (IV) (NCT02966301)
  • 14 Nov 2016 Medsenic plans the phase II GvHD-ATO trial for Graft-versus-host disease (Adjunctive treatment) in France (IV) (NCT02966301)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top